Long-acting injectable PrEP (cabotegravir, Apretude) is now an option
alongside daily oral tenofovir/emtricitabine and on-demand (2-1-1) dosing.
See HIV Prevention — PrEP & PEP.
Gonorrhoea remains a dual-therapy, resistance-driven target: ceftriaxone
500 mg IMI plus azithromycin 1 g PO for uncomplicated genital/anorectal
infection, with a higher azithromycin dose for pharyngeal infection and a
higher ceftriaxone dose for gonococcal conjunctivitis; local resistance
patterns and susceptibility results should still be checked.
See Gonorrhoea.
The syphilis outbreak in Aboriginal and Torres Strait Islander
communities that began in Queensland has continued to spread, and multiple
outbreaks are now running concurrently across Australia — check current
public health alerts for the affected regions rather than relying on a fixed
list. See Syphilis.
The National HPV Vaccination Program uses 9-valent Gardasil 9, covering
more genotypes than the original quadrivalent vaccine.
See Anogenital Warts (HPV).
Mpox vaccination (JYNNEOS/MVA-BN) now covered: ATAGI eligibility,
2 × 0.5 mL SC 28 days apart, PEP within 14 days, best protection 2 weeks
after dose 2 (~80%), side effects and contraindications (Immunisation
Handbook Jan 2026; NSW Health Feb 2026). See Mpox
(2026-09-17).
New pages added
Mpox (2026-09-01) — presentation and
complications, specimen collection and testing indications, supportive
management and when to involve infectious diseases/sexual health
specialists, isolation criteria and transmission risk via semen.